Table 6 Treatments prescribed during the index month
Population ‘All’ | Population 1 | Population 2 | Other coughs | Cough-variant asthma | Atopic/allergic cough | |
|---|---|---|---|---|---|---|
N = 6,038 | N = 3,500 | N = 2,538 | N = 1,444 | N = 1,026 | N = 105 | |
Any medication of interest | 4,860 (80.5%) | 3,115 (89.0%) | 1,745 (68.8%) | 997 (69.0%) | 722 (70.4%) | 76 (72.4%) |
Central antitussives only | 194 (4.0%) | 169 (5.4%) | 25 (1.4%) | 21 (2.1%) | 4 (0.6%) | 0 (0.0%) |
Antiallergic agents (all) | 2,588 (53.3%) | 1,628 (52.3%) | 960 (55.0%) | 503 (50.5%) | 429 (59.4%) | 52 (68.4%) |
Without central antitussives | 2,493 (51.3%) | 1,544 (49.6%) | 949 (54.4%) | 496 (49.7%) | 427 (59.1%) | 51 (67.1%) |
In combination with central antitussives | 95 (2.0%) | 84 (2.7%) | 11 (0.6%) | 7 (0.7%) | 2 (0.3%) | 1 (1.3%) |
Expectorant (all) | 2,331 (48.0%) | 1,654 (53.1%) | 677 (38.8%) | 402 (40.3%) | 281 (38.9%) | 24 (31.6%) |
Without central antitussives | 1,990 (40.9%) | 1,392 (44.7%) | 598 (34.3%) | 348 (34.9%) | 256 (35.5%) | 21 (27.6%) |
In combination with central antitussives | 341 (7.0%) | 262 (8.4%) | 79 (4.5%) | 54 (5.4%) | 25 (3.5%) | 3 (3.9%) |
Antimicrobialsa (all) | 1,672 (34.4%) | 1,245 (40.0%) | 427 (24.5%) | 271 (27.2%) | 161 (22.3%) | 12 (15.8%) |
Without central antitussives | 1,224 (25.2%) | 886 (28.4%) | 338 (19.4%) | 205 (20.6%) | 138 (19.1%) | 10 (13.2%) |
In combination with central antitussives | 448 (9.2%) | 359 (11.5%) | 89 (5.1%) | 66 (6.6%) | 23 (3.2%) | 2 (2.6%) |
ICS and LABA combination (all) | 1,404 (28.9%) | 901 (28.9%) | 503 (28.8%) | 198 (19.9%) | 309 (42.8%) | 25 (32.9%) |
Without central antitussives | 1,049 (21.6%) | 622 (20.0%) | 427 (24.5%) | 158 (15.8%) | 265 (36.7%) | 23 (30.3%) |
In combination with central antitussives | 355 (7.3%) | 279 (9.0%) | 76 (4.4%) | 40 (4.0%) | 44 (6.1%) | 2 (2.6%) |
Herbal medicine (all) | 1,113 (22.9%) | 781 (25.1%) | 332 (19.0%) | 264 (26.5%) | 67 (9.3%) | 8 (10.5%) |
Without central antitussives | 1,047 (21.5%) | 723 (23.2%) | 324 (18.6%) | 258 (25.9%) | 66 (9.1%) | 6 (7.9%) |
In combination with central antitussives | 66 (1.4%) | 58 (1.9%) | 8 (0.5%) | 6 (0.6%) | 1 (0.1%) | 2 (2.6%) |
Corticosteroids (all) | 1,080 (22.2%) | 636 (20.4%) | 444 (25.4%) | 259 (26.0%) | 176 (24.4%) | 15 (19.7%) |
Without central antitussives | 716 (14.7%) | 366 (11.7%) | 350 (20.1%) | 197 (19.8%) | 150 (20.8%) | 11 (14.5%) |
In combination with central antitussives | 364 (7.5%) | 270 (8.7%) | 94 (5.4%) | 62 (6.2%) | 26 (3.6%) | 4 (5.3%) |
Bronchodilatorsb (all) | 914 (18.8%) | 694 (22.3%) | 220 (12.6%) | 124 (12.4%) | 99 (13.7%) | 8 (10.5%) |
Without central antitussives | 287 (5.9%) | 170 (5.5%) | 117 (6.7%%)) | 62 (6.2%) | 60 (8.3%) | 2 (2.6%) |
In combination with central antitussives | 627 (12.9%) | 524 (16.8%) | 103 (5.9%) | 62 (6.2%) | 39 (5.4%) | 6 (7.9%) |
Drugs for peptic ulcer treatment (all) | 718 (14.8%) | 436 (14.0%) | 282 (16.2%) | 145 (14.5%) | 127 (17.6%) | 18 (23.7%) |
Without central antitussives | 691 (14.2%) | 412 (13.2%) | 279 (16.0%) | 143 (14.3%) | 126 (17.5%) | 18 (23.7%) |
In combination with central antitussives | 27 (0.6%) | 24 (0.8%) | 3 (0.2%) | 2 (0.2%) | 1 (0.1%) | 0 (0.0%) |
Drugs for improvement of GI motility function (all) | 210 (4.3%) | 107 (3.4%) | 103 (5.9%) | 55 (5.5%) | 43 (6.0%) | 8 (10.5%) |
Without central antitussives | 205 (4.2%) | 102 (3.3%) | 103 (5.9%) | 55 (5.5%) | 43 (6.0%) | 8 (10.5%) |
In combination with central antitussives | 5 (0.1%) | 5 (0.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |